Calcimedica, INC Form 4 insider transactions

CalciMedica, Inc.'s Chief Financial Officer, Stephen Bardin, acquired 1,000 shares of common stock at $1.69 per share, increasing his direct beneficial ownership to 41,000 shares.

CalciMedica's Chief Financial Officer, Stephen Bardin, reports the acquisition of stock options.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reports the acquisition of employee stock options.

Michael J. Dunn, President and COO of CalciMedica, reports the acquisition of employee stock options.

Eric W. Roberts, Chief Business Officer of CalciMedica, Inc., reports the acquisition of stock options.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, reports the acquisition of stock options.

Rachel A. Leheny, CEO of CalciMedica, Inc., reports the acquisition of 285,000 employee stock options.

Director Alan Glicklich of CalciMedica, Inc. was granted stock options for 20,000 shares on January 15, 2025.

Fred A. Middleton, a director at CalciMedica, acquired 4,800 shares of common stock at $2.65 per share on December 6, 2024.

Eric W. Roberts, Chief Business Officer of CalciMedica, amends a previous SEC Form 4 filing to include the purchase of 3,000 shares of common stock held in his Roth IRA.

Sanderling Venture Partners and related entities report acquiring additional shares of CalciMedica, Inc. common stock at $3.75 per share.

Director Fred A. Middleton reports purchasing shares of CalciMedica, Inc. both directly and indirectly through associated investment funds.

CalciMedica's CEO, Rachel Leheny, recently purchased 20,000 shares of the company's common stock at a price of $3.75 per share.

Eric W. Roberts, Chief Business Officer of CalciMedica, Inc., reports the purchase of 53,333 shares of common stock at $3.75 per share on November 1, 2024.

Director Robert N. Wilson reports the acquisition of 53,333 shares of CalciMedica, Inc. common stock at a price of $3.75 per share on November 1, 2024.

Michael J. Dunn, President and COO of CalciMedica, Inc., exercised stock options to acquire 11,761 shares of common stock at $1.39 per share.

Director Frederic Guerard acquired 10,000 stock options in CalciMedica, Inc. at an exercise price of $4.16 on August 27, 2024.

Director Eric Bjerkhot acquired 10,000 stock options in CalciMedica, Inc. on August 27, 2024.

Director Allan Shaw acquired stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16 on August 27, 2024.

Director Fred A. Middleton receives stock options in CalciMedica, Inc.

Director Robert N. Wilson reports acquisition of stock options in CalciMedica, Inc.

Michael J. Dunn, President and COO of CalciMedica, Inc., reports the acquisition of employee stock options.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reports the acquisition of employee stock options.

Eric W. Roberts, Chief Business Officer of CalciMedica, Inc., reports the acquisition of stock options.

Sudarshan Hebbar, Chief Medical Officer of CalciMedica, acquired stock options for 82,500 shares on August 27, 2024.

CalciMedica's CEO, Rachel Leheny, reports the acquisition of 115,000 employee stock options.

CalciMedica's CEO, Rachel Leheny, recently purchased 1,000 shares of the company's common stock at an average price of $4.1898 per share.

Eric W. Roberts, Chief Business Officer of CalciMedica, recently acquired additional shares of the company's common stock through multiple transactions.

Director Robert N. Wilson of CalciMedica, Inc. recently purchased 54,000 shares of common stock at an average price of $3.719 per share.

Eric W. Roberts, Chief Business Officer of CalciMedica, recently acquired 5,000 shares of common stock at $4.04 per share, increasing his beneficial ownership.